Inactive Instrument

Affymax, Inc. Nasdaq

Equities

US00826A1097

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014	Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer	CI
2014	Affymax Seeks Acquisitions	CI

Affymax, Inc. : Affymax to Present at the J.P. Morgan Healthcare Conference

January 04, 2013 at 02:35 am IST

MarketScreener.com By

Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the 31^st Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2013 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) in San Francisco.

A live webcast of the presentation will be available on the investors section of the Company's website at http://www.investors.affymax.com/events.cfm. A replay will also be available for 30 days following the presentation.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses.

The company's first marketed product, OMONTYS^® (peginesatide) Injection, was approved by the U.S. Food and Drug Administration (FDA) in March 2012. For additional information, please visit www.affymax.com.

Affymax, Inc.
Alexandra Santos, 650-812-8961
Associate Director, Corporate Communications

Latest news about Affymax, Inc.

Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer	27/14/27	CI
Affymax Seeks Acquisitions	26/14/26	CI
Affymax, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014	01/14/01	CI
Affymax Terminates Omontys' Product Collaboration and License Agreement with Takeda Pharmaceutical Company, Effective September 10, 2014	16/14/16	CI
Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement	14/14/14	CI
Affymax To Review Strategic Options	13/14/13	CI
Affymax, Inc. Auditor Raises 'Going Concern' Doubt	01/14/01	CI
Affymax, Inc. Executes a Seventh Amendment to Lease Agreement	21/13/21	CI
Affymax, Inc. Announces Management Changes	07/13/07	CI
Affymax, Inc.(OTCPK:AFFY) dropped from NASDAQ Composite Index	05/13/05	CI
Affymax, Inc.(OTCPK:AFFY) dropped from NASDAQ Biotechnology Index	19/13/19	CI
Affymax, Inc. to Terminate John Orwin as Chief Executive Officer After May 15, 2013	15/13/15	CI
Affymax, Inc. to Reduce Workforce Amid Product Investigation	24/13/24	CI
Affymax, Inc. Enters into a Letter Agreement with Oxford Finance Corporation and Silicon Valley Bank	05/13/05	CI
Affymax, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012	02/13/02	CI
Affymax, Inc. Auditor Raises 'Going Concern' Doubt	02/13/02	CI
Affymax Announces Reduction in Force to Align Resources Around Ongoing Product Investigation	19/13/19	CI
Affymax, Inc. may file for Bankruptcy	18/13/18	CI
Affymax Seeks Strategic Alternatives	18/13/18	CI
Transcript : Affymax, Inc. - Special Call	25/13/25
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection	25/13/25	CI
Affymax, Inc. Announces Executive Changes	01/13/01	CI
Affymax, Inc. and Takeda Pharmaceuticals Announces Pivotal Phase 3 Data on the Safety and Efficacy of OMONTYS(R) (peginesatide) Injection	24/13/24	CI
Transcript : Affymax, Inc. Presents at 31st Annual JPMorgan Healthcare Conference, Jan-10-2013 01:00 PM	11/13/11
Transcript : Affymax, Inc. Presents at Deutsche Bank's 5th Annual dbAccess BioFEST 2012, Dec-03-2012 02:15 PM	04/12/04

Chart Affymax, Inc.

Duration

Period

More charts

Company Profile

Affymax, Inc. is a biopharmaceutical company. The Companyâs product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Companyâs product, OMONTYS.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LONZA GROUP AG	+38.65%	3.91TCr
IQVIA HOLDINGS INC.	-8.62%	3.88TCr
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	3.12TCr
ICON PUBLIC LIMITED COMPANY	+10.74%	2.59TCr
CELLTRION, INC.	-13.50%	2.58TCr
UNITED THERAPEUTICS CORPORATION	+44.87%	1.41TCr
MEDPACE HOLDINGS, INC.	+34.36%	1.31TCr
BIO-TECHNE CORPORATION	-7.14%	1.13TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	1.07TCr

Other Biotechnology & Medical Research